COVID-19 diagnostics surge as industry prepares for spike in at-home testing

Quinn Rooney via Getty Images

Note from the editor

Demand for COVID-19 tests is again surging as the Biden administration last month announced it will spend an additional $1 billion, on top of the previous $2 billion outlay, to get more rapid at-home coronavirus tests into the U.S. market.

Companies like Abbott Laboratories and Quidel are riding the latest testing wave and hiking their revenue forecasts, even as the average number of new coronavirus cases has fallen steadily.

After the rollercoaster change in COVID-19 test demand, from sky high over the winter to rock bottom as the vaccine rollout advanced, and then back up again as the delta variant took hold, the question is what happens in the fourth quarter and into 2022.    

In the meantime, with the unprecedented demand for rapid at-home coronavirus tests, medtechs are looking to sell over-the-counter and direct-to-consumer diagnostics for a myriad of other diseases beyond COVID-19 that don't have to be performed at a hospital, physician's office or pharmacy. 

One of the long-term impacts of the pandemic on the industry and healthcare are the fast and convenient options that home testing and sample collection will provide to consumers going forward.  

Thermo Fisher, Hologic ride wave of COVID-19 test demand, for now

• Published Nov. 2, 2021

Quidel hikes revenue forecast, riding COVID-19 testing wave

• Published Oct. 8, 2021

Labcorp, PerkinElmer latest to target COVID-flu combo test market

• Published Oct. 7, 2021

FDA tells COVID-19 test makers to assess impact of variants in new EUA conditions

• Published Sept. 24, 2021

Abbott, Quest, Quidel likely to benefit from Biden's COVID-19 testing push

• Published Sept. 10, 2021

Jennifer Doudna-founded CRISPR biotech raises cash to move beyond diagnostics

Mammoth Biosciences has accelerated plans to make gene editing medicines.

• Published Sept. 9, 2021

COVID-19 diagnostics surge as industry prepares for post-pandemic testing

After the rollercoaster change in COVID-19 test demand, the question is what happens in the fourth quarter and into 2022. With an unprecedented demand for rapid at-home coronavirus tests, medtechs are looking post-pandemic to sell over-the-counter and direct-to-consumer diagnostics for a myriad of other diseases beyond COVID-19.

included in this trendline
  • Thermo Fisher, Hologic ride wave of COVID-19 test demand, for now
  • Labcorp, PerkinElmer latest to target COVID-flu combo test market
  • Abbott, Quest, Quidel likely to benefit from Biden's COVID-19 testing push